Tougher Tregs

Casebia Therapeutics is using gene editing to engineer autologous Tregs with more durable immunosuppressive activity than unmodified Tregs, and plans to use the cells to treat a variety of autoimmune diseases.

Casebia is a JV formed by CRISPR Therapeutics AG and Bayer AG with IP from the former and funding and disease-relevant experience from the latter. The JV is applying the biotech’s gene editing platform to indications outside both parent companies’ core programs. ...